Shreya Kanth, M.D.

My research focus is studying the cellular mechanisms of acute lung in translational and basic models including endotoxin-induced lung injury, acute respiratory distress syndrome (ARDS), and COVID-19.

Since 2020, I have been actively involved in a clinical research protocol investigating the natural history of patients who have recovered from COVID-19 infection (COVIDARC-19 Natural History Protocol). Through this protocol, I have published on the evolution of the lung proteome longitudinally in patients with mild to moderate COVID-19. We are currently characterizing the microbiome in this cohort through extramural collaborations.

Additionally, I have been investigating the novel role of a neuroimmune protein, semaphorin 5A, in the context of endotoxin-induced lung injury. I am currently studying the immune function of this protein in modulation of early lung inflammation at in-vitro, in-vivo levels and in human models of lung inflammation, including endotoxin-induced lung injury and acute respiratory distress syndrome (ARDS).

My current research endeavor is to understand immune and inflammatory mechanisms in patients on venovenous extracorporeal membrane oxygen (VV-ECMO) for ARDS, by linking biologic mechanisms to clinical outcomes using a multi-omics approach, and through collaboration with extramural VV-ECMO centers of excellence.

Publications

Longitudinal analysis of the lung proteome reveals persistent repair months after mild to moderate COVID-19

Alterations in the plasma proteome persist ten months after recovery from mild to moderate SARS-CoV-2 infection

Personalized Sepsis Treatment: Are We There Yet?

The Role of Semaphorins and Their Receptors in Innate Immune Responses and Clinical Diseases of Acute Inflammation

IL-4 Induces IL17Rb Gene Transcription in Monocytic Cells with Coordinate Autocrine IL-25 Signaling